Skip to main content
    R

    Rockwell Medical Inc (RMTI)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $6.76
    -0.27 (-3.84%)

    Market Cap: $27.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Rockwell Medical Inc (RMTI) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Rockwell Medical (RMTI) is expected to report earnings on Mar 24, 2027. In the quarter ended Sep 30, 2026, Rockwell Medical reported EPS of -$0.59, below the -$0.18 estimate. It beat the EPS estimate in 2 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    43%(17/40)
    Avg Surprise
    -1.21%

    Upcoming Estimates

    Reports Mar 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.07 - -$0.07
    4 analysts
    Revenue Consensus
    $19.39M
    Range$18.50M - $20.09M
    4 analysts

    Next Report

    RMTI has an expected report date of Mar 24, 2027.

    RMTI Earnings Call

    The latest RMTI earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, RMTI beat 17, missed 20 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $19.12M, up 20.0% from $15.93M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.59-$0.18-$0.23 - -$0.13-227.78%MissN/A20 up, 1 downNov 12, 2026$19.12M
    Jun 30, 2026-$0.34-$0.17-$0.30 - -$0.17-100.00%MissN/A21 up, 0 downAug 13, 2026$17.78M
    Mar 31, 2026-$0.40-$0.25-$0.40 - -$0.10-60.00%MissN/A20 up, 0 downMay 7, 2026$17.34M
    Dec 31, 2025-$0.01-$0.05N/A+77.78%BeatN/A20 up, 0 downMar 26, 2026$18.35M
    Sep 30, 2025-$0.50-$0.45-$0.50 - -$0.40-11.11%Miss-200.0%22 up, 0 downNov 12, 2025$15.93M
    Jun 30, 2025-$0.50-$0.50N/A0.00%In line-600.0%N/A0 up, 0 downAug 14, 2025$16.07M
    Mar 31, 2025-$0.40-$0.50N/A+20.00%BeatN/AN/A0 up, 0 downMay 12, 2025$18.91M
    Dec 31, 2024-$0.02$0.02N/A-200.00%MissN/AN/A0 up, 0 downMar 20, 2025$24.66M
    Sep 30, 2024$0.50$0.10$0.10 - $0.10+400.00%BeatN/A20 up, 0 downNov 12, 2024$28.32M
    Jun 30, 2024$0.10-$0.35-$0.40 - -$0.30+128.57%BeatN/A20 up, 0 downAug 8, 2024$25.83M
    Mar 31, 2024-$0.60-$0.40-$0.50 - -$0.30-50.00%MissN/A20 up, 0 downMay 14, 2024$22.68M
    Dec 31, 2023-$0.05-$0.07-$0.08 - -$0.06+28.57%BeatN/A20 up, 0 downMar 21, 2024$22.09M
    Sep 30, 2023-$0.87-$0.90-$1.20 - -$0.90+3.33%BeatN/A20 up, 0 downNov 14, 2023$23.77M
    Jun 30, 2023-$1.69-$1.20-$1.20 - -$1.20-40.83%MissN/A10 up, 0 downAug 14, 2023$18.08M
    Mar 31, 2023-$0.10-$0.16-$0.18 - -$0.15+37.50%BeatN/A20 up, 0 downMay 15, 2023$19.67M
    Dec 31, 2022-$1.40-$3.90-$3.90 - -$3.90+64.10%BeatN/A20 up, 0 downMar 30, 2023$19.31M
    Sep 30, 2022-$4.00-$3.70-$6.00 - -$3.70-8.11%MissN/A20 up, 0 downNov 14, 2022$18.69M
    Jun 30, 2022-$5.60-$8.10N/A+30.86%BeatN/AN/A0 up, 0 downAug 15, 2022$18.68M
    Mar 31, 2022-$8.40-$7.70N/A-9.09%MissN/A10 up, 0 downApr 8, 2022$16.12M
    Dec 31, 2021-$0.09-$0.09N/A-0.01%MissN/A10 up, 0 downDec 31, 2021$15.33M
    Sep 30, 2021-$8.80-$8.25-$8.80 - -$7.70-6.67%MissN/A21 up, 0 downNov 15, 2021$15.99M
    Jun 30, 2021-$9.90-$8.80-$8.80 - -$8.80-12.50%MissN/A2N/AAug 16, 2021$15.14M
    Mar 31, 2021-$8.80-$9.90-$9.90 - -$9.90+11.11%BeatN/A1N/AMay 17, 2021$15.47M
    Dec 31, 2020-$0.99-$0.93-$0.99 - -$0.88-6.45%MissN/A2N/AMar 31, 2021$15.16M
    Sep 30, 2020-$11.00-$7.70-$14.30 - -$7.70-42.86%MissN/A2N/ANov 9, 2020$15.28M
    Jun 30, 2020-$9.57-$15.40-$16.50 - -$14.30+37.86%BeatN/A2N/AAug 10, 2020$15.90M
    Mar 31, 2020-$13.20-$13.20-$15.40 - -$12.100.00%In lineN/A3N/AMay 11, 2020$15.86M
    Dec 31, 2019-$1.21-$1.36-$1.54 - -$1.21+11.03%BeatN/A3N/AMar 12, 2020$15.49M
    Sep 30, 2019-$13.20-$17.23-$19.80 - -$13.20+23.39%BeatN/A3N/ANov 11, 2019$15.41M
    Jun 30, 2019-$19.80-$17.60-$20.90 - -$12.10-12.50%MissN/A4N/AAug 8, 2019$14.85M
    Mar 31, 2019-$1.65-$1.98-$1.98 - -$1.98+16.67%BeatN/A1N/AMay 9, 2019$15.56M
    Dec 31, 2018-$1.87-$1.43-$1.43 - -$1.43-30.77%MissN/A1N/AMar 14, 2019$16.85M
    Sep 30, 2018-$1.10-$1.65N/A+33.33%BeatN/AN/AN/ANov 9, 2018$16.67M
    Jun 30, 2018-$2.42-$1.43-$1.43 - -$1.43-69.23%MissN/A1N/AAug 14, 2018$14.91M
    Mar 31, 2018-$1.43-$1.54-$1.54 - -$1.54+7.14%BeatN/A1N/AMay 10, 2018$14.95M
    Dec 31, 2017-$19.80-$13.20-$14.30 - -$13.20-50.00%MissN/A2N/AMar 15, 2018$14.84M
    Sep 30, 2017-$11.00-$11.00-$12.10 - -$11.000.00%In lineN/A3N/ANov 8, 2017$14.63M
    Jun 30, 2017-$15.40-$11.00-$11.00 - -$11.00-40.00%MissN/A1N/AAug 9, 2017$13.24M
    Mar 31, 2017-$0.99-$0.93N/A-6.45%MissN/AN/AN/AMay 9, 2017$14.59M
    Dec 31, 2016-$11.00-$11.55N/A+4.76%BeatN/AN/AN/AMar 15, 2017$13.39M
    Last 40 quarters

    Estimates made before a stock split are shown on the same share basis as the reported EPS.

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$0.02 the year before. It was -$33.99 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.41N/A
    Dec 31, 2024-$0.02N/A
    Dec 31, 2023-$2.71N/A
    Dec 31, 2022-$19.40N/A
    Dec 31, 2021-$27.59N/A
    Dec 31, 2020-$34.76N/A
    Dec 31, 2019-$35.86N/A
    Dec 31, 2018-$6.82N/A
    Dec 31, 2017-$47.19N/A
    Dec 31, 2016-$33.99N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,700 words across 5 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,6905
    2026Q2Jun 30, 20263,8626
    2026Q1Mar 31, 20262,4575
    2025Q4Dec 31, 20254,9286
    2025Q3Sep 30, 20253,1237
    2025Q2Jun 30, 20252,7036
    2025Q1Mar 31, 20252,4406
    2024Q3Sep 30, 20243,3076

    2026Q3 Earnings Call

    Opening remarks

    Laura Garrett Executive Director of Investor Relations Good morning, everyone, and thank you for joining us for this update on Rockwell Medical. I am thrilled to be joining you today as Rockwell Medical's new Executive Director of Investor Relations. I look forward to working closely with our community and partnering with you moving forward. Joining me on today's conference call are Dr. Mark Strobeck, Rockwell Medical's President and CEO, and Jesse Neri, Rockwell Medical's Chief Financial Officer. Before we begin, I would like to remind you that this conference call will contain forward-looking statements about Rockwell Medical within the meaning of the federal securities laws, including but not limited to the types of statements identified as forward-looking in our annual report on Form 10-K and our subsequent periodic reports filed with the SEC. These statements are subject to risks and uncertainties that could cause results to differ. Please note that these forward-looking statements reflect our opinions and expectations only as of today. Except as required by law, we have no obligation to update or revise these forward-looking statements in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our periodic reports filed with the SEC. Rockwell Medical's quarterly report on Form 10-Q for the three months ended September 30, 2026, was filed prior to this call. The reconciliation of non-GAAP measures we discuss on today's call can be found in today's press release. Our Form 10-Q and other reports filed with the SEC, along with today's press release and a replay of today's conference call, can be found on Rockwell Medical's website under the Investors section. And with that, I will turn the call over to Rockwell Medical's President and CEO, Dr. Mark Strobeck. Mark?

    Mark Strobeck President and CEO Thank you, Laura, and good morning, everyone. Thank you for joining us today for Rockwell Medical's third quarter 2026 Earnings Conference Call and Webcast. We are excited to welcome Laura, who recently joined as our new Executive Director of Investor Relations. Laura brings to Rockwell more than 30 years of experience in investor relations and capital markets, especially within the healthcare sector. Laura now leads our investor relations function and will serve as a key liaison between Rockwell Medical and our shareholders, analysts, prospective investors, and the broader investment community. This morning, our remarks are organized around three key topics. One, the continued execution of our plan for our core hemodialysis business; two, the future impact of our pending acquisition of a global hemodialysis business; and three, the potential opportunity inherent in the new U.S. Health and Human Services Kidney Care National Plan.

    Frequently Asked Questions About RMTI

    When is Rockwell Medical's next earnings date?

    Rockwell Medical's next earnings report is expected for Mar 24, 2027.

    Did RMTI beat earnings estimates last quarter?

    No. Rockwell Medical reported EPS of -$0.59 for the quarter ended Sep 30, 2026, below the -$0.18 estimate by 227.78%.

    What EPS do analysts expect from RMTI next quarter?

    The consensus EPS estimate for Rockwell Medical for the quarter ending Dec 31, 2026 is -$0.07 from 4 analysts, with estimates from -$0.07 to -$0.07.

    How often does RMTI beat earnings estimates?

    Rockwell Medical beat the EPS estimate in 2 of the last 8 quarters, with an average surprise of -62.64%.